Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report)-Reference-Cited by-同舟云学术

Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report)

Published:2017-12-27 Issue:3 Volume:38 Page:219-229
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Takahashi Tomohiko,Hayata Satoru,Kobayashi Akihiro,Onaka Yuna,Ebihara Takeshi,Hara Terufumi

Funder

GSK Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-017-0602-4/fulltext.html

Reference27 articles.

1. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.

2. Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. CHEST. 2015;148(4):1043–54.

3. Akagi S, Nakamura K, Matsubara H, et al. Epoprostenol therapy for pulmonary arterial hypertension. Acta Med Okayama. 2015;69(3):129–36.

4. Tamura Y, Channick RN. New paradigm for pulmonary arterial hypertension treatment. Curr Opin Pulm Med. 2016;22(5):429–33.

5. Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71(1):73–83.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of pressure and flow changes to resistance reduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients;ERJ Open Research;2023-12-07

2. Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: Results from the Korean post‐marketing surveillance;Pharmacoepidemiology and Drug Safety;2023-07-27

3. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study);Arthritis Research & Therapy;2019-10-26

4. Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice;Circulation Reports;2019-06-10

5. Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn;Basic & Clinical Pharmacology & Toxicology;2018-07-19